Table 2 The enriched KEGG pathways of psychiatric disorders
From: A new bioinformatic insight into the associated proteins in psychiatric disorders
Term | Description | Count | P value |
|---|---|---|---|
KEGG:04080 | Neuroactive ligand-receptor interaction | 54 | 2.15E−10 |
KEGG:04020 | Calcium signaling pathway | 34 | 6.88E−06 |
KEGG:04720 | Long-term potentiation | 18 | 3.01E−05 |
KEGG:04730 | Long-term depression | 18 | 3.70E−05 |
KEGG:05215 | Prostate cancer | 19 | 3.37E−04 |
KEGG:04540 | Gap junction | 18 | 9.74E−04 |
KEGG:04150 | mTOR signaling pathway | 12 | 0.003294 |
KEGG:05012 | Parkinson’s disease | 21 | 0.004578 |
KEGG:05216 | Thyroid cancer | 8 | 0.008593 |
KEGG:05220 | Chronic myeloid leukemia | 14 | 0.008781 |
KEGG:00250 | Alanine, aspartate and glutamate metabolism | 8 | 0.012514 |
KEGG:04012 | ErbB signaling pathway | 15 | 0.012769 |
KEGG:05218 | Melanoma | 13 | 0.014087 |
KEGG:05214 | Glioma | 12 | 0.014554 |
KEGG:05200 | Pathways in cancer | 40 | 0.015047 |
KEGG:00563 | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | 7 | 0.015127 |
KEGG:05010 | Alzheimer’s disease | 23 | 0.016819 |
KEGG:04916 | Melanogenesis | 16 | 0.017224 |
KEGG:04142 | Lysosome | 18 | 0.017275 |